Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE - China Phase 3 trial for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). nnIn August 2022, Nuance Pharma received clearance from the Center of Drug Evaluation (“CDE”) for its Investigational New Drug (“IND”) application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of COPD in mainland China. Nuance Pharma initiated a Phase 1 trial with ensifentrine in healthy volunteers in March 2023. nn“We are pleased our development partner, Nuance Pharma, has begun pivotal studies in COPD with ensifentrine in mainland China,” said D
Nuance Pharma has announced partnership with DKSH Hong Kong (DKSH HK) Business Unit Healthcare to launch Bentrio nasal spray in Hong Kong and Macau, marking the very first milestone of Nuance Pharma's commercial expansion in the APAC market.
The Chinese Center for Drug Evaluation (CDE) has granted clearance for Nuance Pharma’s Investigational New Drug (IND) application for a Phase III clinical trial of an MVA-BN RSV vaccine for use in adults with respiratory syncytial virus (RSV) infection in the country.
As three big players get set to reveal pivotal data for adult RSV vaccines, Bavarian Nordic seals a deal for its candidate that could still claim a sizeable niche if a late-stage trial delivers.
Microsoft has closed on its approximately $16 billion acquisition of speech recognition company Nuance.